Intangible Assets and Goodwill (Tables)

3 Months Ended

Mar. 29, 2020

Goodwill and Intangible Assets Disclosure [Abstract]

Intangible Assets and Goodwill

(Dollars in Millions)	March 29, 2020		December 29, 2019
Intangible assets with definite lives:
Patents and trademarks — gross	$	36,214	36,634
Less accumulated amortization	13,857		13,154
Patents and trademarks — net	22,357		23,480
Customer relationships and other intangibles — gross	22,084		22,056
Less accumulated amortization	9,728		9,462
Customer relationships and other intangibles — net*	12,356		12,594
Intangible assets with indefinite lives:
Trademarks	6,829		6,922
Purchased in-process research and development (1)	5,796		4,647
Total intangible assets with indefinite lives	12,625		11,569
Total intangible assets — net	$	47,338	47,643

*The majority is comprised of customer relationships

⁽¹⁾ In the fiscal first quarter of 2020, the Company completed the acquisition of bermekimab and certain related assets from XBiotech Inc. as well as the acquisition of all outstanding shares in Verb Surgical Inc. and recorded in-process research and development intangible assets of $0.8 billion and $0.4 billion, respectively.

Goodwill

Goodwill as of March 29, 2020 was allocated by segment of business as follows:

(Dollars in Millions)	Consumer Health			Pharmaceutical		Medical Devices		Total
Goodwill at December 29, 2019	$	9,736		9,169		14,734		33,639
Goodwill, related to acquisitions	—			1		156		157
Currency translation/Other	(223		)	(96	)	(6	)	(325	)
Goodwill at March 29, 2020	$	9,513		9,074		14,884		33,471

Intangible Asset Amortization Expense

The estimated amortization expense for approved products, before tax, for the five succeeding years is approximately:

(Dollars in Millions)
2020	2021	2022	2023	2024
$4,500	4,300	4,100	4,100	4,000